このエピソードについて
Prof Noel Clarke and Dr Bertrand Tombal
Prof Noel Clarke (The Christie Hospital, Manchester, UK) and Dr Bertrand Tombal (Saint-Luc Hospital, Brussels, Belgium) discuss the evolving treatment landscape in prostate cancer for ecancertv at ECC 2015, with a particular focus on new data and dialogue arising from the conference.
They first comment on the potential of TAK-385, a new oral gonadotropin-releasing hormone antagonist. Phase II study findings presented at the meeting showed that it had a good efficacy and safety profile and might thus offer an alternative to existing GnRH androgen deprivation therapies that currently have to be injected.
They also discuss new findings on neoadjuvant therapy for patients undergoing prostatectomy and the results of the STAMPEDE trial. The STAMPEDE trial looked at using docetaxel, zoledronic acid, or both, versus standard of care for hormone-naïve, high-risk, localized or metastatic prostate cancer.
Prof Noel Clarke (The Christie Hospital, Manchester, UK) and Dr Bertrand Tombal (Saint-Luc Hospital, Brussels, Belgium) discuss the evolving treatment landscape in prostate cancer for ecancertv at ECC 2015, with a particular focus on new data and dialogue arising from the conference.
They first comment on the potential of TAK-385, a new oral gonadotropin-releasing hormone antagonist. Phase II study findings presented at the meeting showed that it had a good efficacy and safety profile and might thus offer an alternative to existing GnRH androgen deprivation therapies that currently have to be injected.
They also discuss new findings on neoadjuvant therapy for patients undergoing prostatectomy and the results of the STAMPEDE trial. The STAMPEDE trial looked at using docetaxel, zoledronic acid, or both, versus standard of care for hormone-naïve, high-risk, localized or metastatic prostate cancer.
英語
アメリカ合衆国
文字起こし 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
このポッドキャストの他のエピソード
Prof Riccardo Audisio - President of the European Society for Surgical Oncology
Prof Audisio talks to ecancertv at ECC 2015 about optimising education about cancer surgery and the need to improve current standards as only 25% of patients receive adequate surgical care.
He also talks about the tre…
Prof Mark Lawler - Chair of the EAPM Research Subgroup
Prof Lawler talks to ecancertv at ECC 2015 about his investigation into disparities across Europe.
He discusses what discoveries he has made, and how economics and resources can affect treatment of cancer patients.
Prof Peter Naredi - University of Gothenburg, Gothenburg, Sweden
Prof Naredi talks to ecancertv at ECC 2015 about the use of surgery in synchronous oligometastatic disease.
In the interview he highlights that two to three decades ago it was rare that patients with metastatic disease would be refe…
Prof Martin Schrappe - University Medical Center Schleswig-Holstein, Kiel, Germany
Prof Schrappe talks to ecancertv at ECC 2015 about improving both the cure rate and the quality of life for survivors of childhood cancers over the next ten years, with the ultimate aim of increasing disease-free an…
Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA
Prof Brastianos talks to ecancertv at ECC 2015 about how unravelling the genetic sequences of cancer that has spread to the brain could offer unexpected targets for treatment.
In the interview she highlights the results of a …
免責: このページに埋め込まれているポッドキャストとアートワークは ecancer.org からのものであり、その所有者の所有物であり、Listen Notes, Inc. と提携または承認されていません。
